Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 4;48(12):0300060520959502. doi: 10.1177/0300060520959502

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — ST2 and IL-33 levels before and after treatment in STEMI patients. The control group (n = 44) and observation group (n = 40) were given oral atorvastatin (80 mg before thrombolytic therapy and subsequent doses of 20 mg/day for 2 months) or a combination of atorvastatin and ticagrelor (initial dose of 180 mg and subsequent doses of 90 mg two times per day for 2 months), respectively. (A) Both groups demonstrated a decrease in ST2 levels, which was significant in the observation group. (B) Both groups demonstrated a decrease in IL-33 levels, which was significant in the observation group. The results are presented as the mean ± standard deviation, and * represents p < 0.05.

ST-segment elevation myocardial infarction, STEMI; ST2, suppression of tumorigenicity 2; IL-33, interleukin-33.